Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - NETs and endocrine tumours

5468 - Tumor Growth Rate and Lenvatinib Efficacy in Radioiodine-refractory Differentiated Thyroid Cancer

Date

22 Oct 2018

Session

Proffered paper session - NETs and endocrine tumours

Presenters

Sophie Leboulleux

Citation

Annals of Oncology (2018) 29 (suppl_8): viii645-viii648. 10.1093/annonc/mdy302

Authors

S. Leboulleux1, E.K. Lee2, L. Bastholt3, M. Tahara4, L.J. Wirth5, S.I. Sherman6, B.G. Robinson7, A. Teng8, P. Joshi8, S. Misir8, C.E. Dutcus8, R.M. Tuttle9, M.J. Schlumberger1

Author affiliations

  • 1 Gustave Roussy, University Paris-Saclay, 94805 - Villejuif/FR
  • 2 Center For Thyroid Cancer, National Cancer Center, Goyang-si/KR
  • 3 Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 4 Head And Neck Medical Oncology, National Cancer Center Hospital East, 277-8577 - Kashiwa/JP
  • 5 Cancer Center, Massachusetts General Hospital, Boston/US
  • 6 Endocrine Neoplasia And Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston/US
  • 7 Kolling Institute Of Medical Research, The University of Sydney, New South Wales/AU
  • 8 Oncology Business Unit, Eisai Inc., 07677 - Woodcliff Lake/US
  • 9 Endocrinology, Memorial Sloan-Kettering Cancer Center, New York/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5468

Background

Patients (pts) with differentiated thyroid cancer (DTC) are a heterogeneous group. Tumor growth rate (TGR) is correlated with life expectancy. Lenvatinib (LEN) is approved for radioiodine-refractory DTC based on the phase 3 SELECT trial. Here we examine TGR and efficacy outcomes from SELECT.

Methods

Per SELECT eligibility criteria, pts had independent radiologic evidence of progression within 13 months prior to randomization (prebaseline) to LEN or placebo (PBO). In this post hoc, exploratory analysis, pre-randomization TGR was assessed per pt as: (sum of target lesions at baseline – sum of target lesions at prebaseline) divided by sum of target lesions at prebaseline, and then divided by the interval of time between the 2 examinations (in mos). Pts were dichotomized: slow TGR (TGR ≤ median TGR of all SELECT pts) vs fast TGR (TGR > median). Subgroups were: baseline liver metastases (yes vs no), age (≤65 vs > 65 y), histology (papillary vs follicular), ECOG PS (0 vs ≥ 1), and baseline thyroid-stimulating hormone (TSH) (≤0.1 vs > 0.1 uIU/mL).

Results

In a multivariate model, TGR of pts on LEN was significantly associated with baseline tumor size, and baseline liver, bone, and other metastases. When comparing treatment arms, LEN improved progression-free survival (PFS) vs PBO in both slow TGR (median 20.2 vs 3.7 mos; HR 0.19; 95% CI 0.12–0.32; P < 0.001) and fast TGR groups (median 14.8 vs 3.5 mos; HR 0.20; 95% CI 0.12–0.33; P < 0.001). PFS of LEN-treated pts was significantly longer in the slow vs fast TGR group (median 20.2 vs 14.8 mos; HR 0.62; 95% CI 0.41–0.94; P = 0.0232). Differences were also seen for PFS between slow and fast TGR groups in pts >65 years, pts with ECOG PS 0, and pts with baseline TSH >0.1 uIU/mL. When comparing treatment arms, overall survival (OS) trends favored LEN over PBO in both slow (medians not reached [NR]; HR 0.53; 95% CI 0.29–0.97) and fast TGR groups (LEN, NR vs PBO, 20.3 mos; HR 0.78; 95% CI 0.43–1.39); however, significance was not achieved in the fast TGR group. Among pts on LEN, OS was similar between slow and fast TGR groups (HR 0.77; 95% CI 0.46–1.29); no trends were seen in subgroup analyses.

Conclusions

In SELECT, LEN conferred benefit over PBO for all pts regardless of TGR; however, PFS was significantly longer in pts with slower TGR.

Clinical trial identification

NCT01321554.

Legal entity responsible for the study

Eisai Inc.

Funding

Eisai Inc.

Editorial Acknowledgement

Editorial support was provided by Oxford PharmaGenesis of Newtown, PA, USA, and was sponsored by Eisai Inc.

Disclosure

S. Leboulleux: Honoraria: Sanofi Genzyme, Bayer; Consulting/advisory role: Sanofi Genzyme; Research funding (institutional support): Bayer, Novartis; Travel/accommodations/expenses: Sanofi Genzyme. E.K. Lee: Consulting/advisory role: Eisai. L. Bastholt: Consulting/advisory role: Merck, BMS, Roche, Eisai, Incyte, Novartis; Travel/accommodations expenses: Merck, BMS, Novartis. M. Tahara: Honoraria: Bayer, Bristol-Myers Squibb, Eisai, Merck Serono, Takeda; Consulting/ advisory role: Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, MSD, Ono Pharmaceutical, Pfizer; Research funding (institutional support): AstraZeneca, Bayer, Boehringer Ingelheim, Eisai, Merck Sharp & Dohme, NanoCarrier, Novartis, Ono Pharmaceutical, Pfizer. L.J. Wirth: Consulting/advisory role: Amgen, Blueprint Medicines, Eisai, Loxo, Merck; Research funding: AstraZeneca, Bayer, Eisai. S.I. Sherman: Grant: Eisai, Pfizer, Genzyme; Personal fees: Eisai, Exelixis, Bayer, Onyx, AstraZeneca, Veracyte, NovoNordisk, Eli Lilly, Genzyme, Roche. B.G. Robinson: Personal fees: Eisai, AstraZeneca, Bayer. A. Teng, P. Joshi, S. Misir, C.E. Dutcus: Employee: Eisai Inc. R.M. Tuttle: Honoraria: Bayer, Eisai, Genzyme, Novo Nordisk; Consulting/advisory role: Eisai, Novo Nordisk; Research funding: AstraZeneca; Travel, accommodations, expenses: Bayer, Eisai, Genzyme, Novo Nordisk. M.J. Schlumberger: Consulting/advisory role: Bayer, Eisai, Ipsen, Sanofi Genzyme; Research funding: Eisai.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings